Torinat 5 — Everolimus 5 mg Tablets, 28 Tablets

Torinat 5 is supplied as tablets containing 5 mg of everolimus.

Qualitative and Quantitative Composition per Tablet:

• Active Ingredient: Everolimus — 5 mg.
• Excipients: Anhydrous lactose, crospovidone, hypromellose, butylated hydroxytoluene, magnesium stearate.

Packaging and Presentation: White to slightly yellowish, round, flat-faced beveled-edge tablets with debossing. 7 tablets per aluminum blister strip. 4 blister strips (total 28 tablets) are packaged in an outer carton displaying Torinat 5 (Everolimus Tablets) along with Natco Pharma corporate graphics and official prescribing information.

Pharmacodynamics:
Everolimus is a potent inhibitor of mammalian target of rapamycin (mTOR). mTOR is a key serine/threonine protein kinase whose activity is aberrantly upregulated in many tumors. mTOR inhibition by everolimus prevents protein translation and transcription required for the cell cycle (via S6K1 and 4E-BP1 suppression). This leads to G1 cell cycle arrest, apoptosis induction, and suppressed angiogenesis.

Pharmacokinetics:

• Absorption: Following oral administration, peak plasma concentrations ($C_{max}$) are reached within 1 to 2 hours. Moderate-fat meals affect absorption rate and extent (consistent administration with or without food is recommended).
• Distribution: Plasma protein binding is approximately 74% (primarily albumin). Volume of distribution is high.
• Metabolism: Metabolized in the liver via the cytochrome P450 isoenzyme CYP3A4 and acts as a substrate for P-glycoprotein (P-gp).
• Elimination: Excreted predominantly via feces (~80%) as metabolites and renally (~5%). Terminal elimination half-life ($T_{1/2}$) averages approximately 30 hours.

Torinat 5 is indicated in adult patients for:

• Advanced Renal Cell Carcinoma: Treatment of advanced renal cell carcinoma following failure of prior VEGF-targeted therapy.
• Neuroendocrine Tumors: Treatment of unresectable or metastatic neuroendocrine tumors of pancreatic, gastrointestinal, or lung origin with progressive disease.
• Hormone-Dependent Breast Cancer: Treatment of advanced hormone-positive HER2-negative breast cancer in combination with exemestane in postmenopausal women following prior non-steroidal aromatase inhibitor therapy.
• Renal Angiomyolipoma: Associated with tuberous sclerosis complex not requiring immediate surgery.

Torinat 5 is administered orally once daily at the same time each day (in the morning) with a glass of water.

Administration Instructions:
Tablets must be swallowed whole without chewing, crushing, or dividing. Take consistently either always with food (low-fat) or always on an empty stomach.

Dosing Regimen:
While standard doses for several indications are 10 mg/day, the 5 mg strength is frequently utilized for individual dose adjustments, managing toxicity reductions, or specialized protocols (e.g., tuberous sclerosis).

Administration of Torinat 5 is contraindicated in:

• Hypersensitivity: Known hypersensitivity to everolimus, other rapamycin derivatives (sirolimus, temsirolimus), or any excipient.
• Severe Hepatic Impairment: Child-Pugh Class C.
• Pregnancy and Lactation: Strictly contraindicated in pregnant or breastfeeding women.
• Pediatric Population: Pediatric use is restricted to strict specialized indications under expert medical supervision.

Everolimus is metabolized via CYP3A4 and is a P-gp substrate:

• Strong CYP3A4 and P-gp Inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit juice): Significantly increase everolimus blood concentrations. Concomitant use should be avoided.
• Strong CYP3A4 Inducers (rifampicin, carbamazepine, phenobarbital, St. John's wort): Significantly decrease everolimus blood concentrations, reducing efficacy. Concomitant use should be avoided.

Pregnancy:
Torinat 5 is contraindicated during pregnancy due to teratogenic and embryo-fetal toxicity risks. Women of childbearing potential must use effective contraception during treatment and for 8 weeks post-therapy.

Lactation:
Excretion into human breast milk has not been studied. Breastfeeding is strictly prohibited during treatment.

The most frequent and clinically significant adverse reactions associated with everolimus include:

• Stomatitis and Oral Ulceration (Very Common): Inflammation of the oral mucosa requiring proper hygiene and rinses.
• Infections: Increased risk of bacterial, fungal, and viral infections, including pneumonia.
• Respiratory System: Non-infectious pneumonitis (interstitial lung disease), cough, dyspnea.
• Gastrointestinal Tract: Diarrhea, nausea, vomiting, abdominal pain, decreased appetite.
• Hematologic Toxicity: Anemia, leukopenia, thrombocytopenia, neutropenia.
• Metabolic Disorders: Hyperglycemia, hypercholesterolemia, hypertriglyceridemia, elevated serum creatinine and liver enzymes.
• Skin & Appendages: Rash, dry skin, pruritus, acne.

Symptoms:
Clinical experience with everolimus overdose in humans is limited. Single doses up to 70 mg showed toxicity profiles consistent with known adverse events (stomatitis, rash, fatigue, laboratory abnormalities).

Treatment:
No specific antidote exists. Supportive and symptomatic care should be administered under close medical supervision.

Storage Requirements for Torinat 5:

• 🌡️ Temperature Range: Store protected from light at temperatures not exceeding 25–30 °C.
• 💧 Moisture Protection: Keep in original blister packaging to protect tablets from moisture.
• 👶 Safety Precautions: Keep strictly out of reach of children.
• ⏳ Shelf Life: Stated on carton and blisters. Do not use past expiration date. Prescription-only hospital medicine.

To verify the authenticity of genuine Torinat 5 manufactured by Natco Pharma, inspect the following features:

• ✅ Corporate Logo: Distinctive blue-green Natco Pharma corporate logo printed on the outer carton and blister foil.
• ✅ Packaging Markings: Clear factory printing displaying Batch No., Mfg. Date, Exp. Date, and product designation Torinat 5 (Everolimus Tablets).
• ✅ Blister Quantity: Standard box contains exactly 4 blister strips of 7 tablets each (total 28 tablets).
• ✅ Print Quality: High-grade packaging artwork without color fading or typography errors.